Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.63 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10467161 | 0.84 | MAPT (0.79) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL10467163 | 0.84 | MAPT (0.79) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL30562843 | 0.83 | MAPT (0.77) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL2032357 | 0.82 | MAPT (0.69) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL2032355 | 0.82 | MAPT (0.69) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL27567539 | 0.79 | CYP1A2 (0.66) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL5598355 | 0.79 | MAPT (1.00) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL5598357 | 0.79 | MAPT (1.00) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL96291 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL6632089 | 0.79 | CYP1A2 (0.70) | ALDH1A1MAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110214012-A | Azole pyrimidines for the treatment of cancer-related diseases | 艾库斯生物科学有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1553949-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7132424-B2 | Monocyclic derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060247231-A1 | Amide and ester matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-11-02 | — | — | US | disclosed |
| US-6977261-B2 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-6974822-B2 | 3-isoquinolinone derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1587516-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004014868-A2 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014354-A1 | 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014880-A1 | CHROMONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014389-A1 | 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP2, MMP3 | ALDH1A1 416/4885MAPT 1633/4885MEN1 1741/4885 |
| US-20060247231-A1 | Amide and ester matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | ALDH1A1 153/4885MAPT 3752/4885MEN1 1941/4885 |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | ALDH1A1 430/4885MAPT 1535/4885MEN1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.